BlackRock’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-2,729,571
| Closed | -$10.1M | – | 5079 |
|
|
2017
Q4 | $10.1M | Buy |
2,729,571
+720,462
| +36% | +$2.95M | ﹤0.01% | 3144 |
|
|
2017
Q3 | $8.22M | Buy |
2,009,109
+73,002
| +4% | +$279K | ﹤0.01% | 3277 |
|
|
2017
Q2 | $7.19M | Buy |
1,936,107
+1,399,496
| +261% | +$5.55M | ﹤0.01% | 3338 |
|
|
2017
Q1 | $2.22M | Buy |
+536,611
| New | +$2.26M | ﹤0.01% | 3622 |
|
|
2016
Q2 | – | Sell |
-550
| Closed | -$4K | – | 3883 |
|
|
2016
Q1 | $4K | Buy |
550
+225
| +69% | +$1.73K | ﹤0.01% | 3396 |
|
|
2015
Q4 | $4K | Hold |
325
| – | – | ﹤0.01% | 3226 |
|
|
2015
Q3 | $5K | Hold |
325
| – | – | ﹤0.01% | 3051 |
|
|
2015
Q2 | $7K | Sell |
325
-143
| -31% | -$2.26K | ﹤0.01% | 3032 |
|
|
2015
Q1 | $5K | Hold |
468
| – | – | ﹤0.01% | 3049 |
|
|
2014
Q4 | $5K | Hold |
468
| – | – | ﹤0.01% | 3089 |
|
|
2014
Q3 | $5K | Buy |
468
+174
| +59% | +$2.66K | ﹤0.01% | 3097 |
|
|
2014
Q2 | $6K | Buy |
294
+279
| +1,860% | +$4.92K | ﹤0.01% | 3097 |
|
|
2014
Q1 | $0 | Buy |
+15
| New | +$246 | ﹤0.01% | 3200 |
|
BlackRock's CASC Position: Q1 2018 in Review
BlackRock sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 2,729,571 shares — an estimated $10.1M sold.
BlackRock first reported a position in CASC in Q1 2014 and held it in 13 quarters. The position peaked at $10.1M in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- BlackRock reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- BlackRock sold 2,729,571 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $10.1M.
- BlackRock first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 13 quarters.
- BlackRock's Cascadian Therapeutics, Inc. position peaked at $10.1M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on BlackRock's 13F filing for Q1 2018, filed 9 May 2018.